Skip to main content
. 2022 Oct;14(10):4055–4072. doi: 10.21037/jtd-22-1185

Figure 7.

Figure 7

Prognostic analysis of the m6A-related lncRNA risk-score model. (A,B) Univariate and multivariate Cox regression analysis of the training set: (A) univariate analysis; (B) multivariate analysis. (C,D) Univariate and multivariate Cox regression analyses of TCGA-LUSC data set: (C) univariate analysis; (D) multivariate analysis. A stratification analysis was performed to confirm whether the risk-score model retained its predictive value in different subgroups. (E) Patients ≤65 years. (F) Patients >65 years. (G) Female patients. (H) Male patients. (I) Patients with T1–2 disease. (J) Patients with T3–4 disease. (K) Patients without lymph node invasion. (L) Patients with lymph node invasion. (M) Patients with stage I–II disease. (N) Patients with stage III–IV disease. T, tumor; M, metastasis; N, node; m6A, N6-methylandenosine; lncRNA, long non-coding RNA; TCGA, The Cancer Genome Atlas; LUSC, lung squamous cell carcinoma.